Module 4: Mechanisms of Resistance
This learning activity has been designated for 2.50 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in this activity.
Learning Objectives
After completing this educational activity, the learner should be better able to:
- Understand the mechanisms involved in imatinib relapse
- State the recommendations regarding early detection of suboptimal response or treatment failure in patients receiving imatinib therapy
- Discuss second-line and third-line treatment options in patients who do not respond adequately to imatinib
- Explain the issues involved in chronic myelogenous leukemia (CML) stem cell survival and its clinical significance
Target Audience
This learning activity is intended for medical oncologists, hematologists, stem cell transplant physicians, and other interested healthcare professionals who manage and treat chronic myelogenous leukemia in the hematology/oncology and transplant patient settings.
Release Date: November 30, 2008
Expiration date: November 30, 2009
(*Please check this box to proceed - required)
Start the Module